Skip to content
Axcess News – Lifestyle
Author:
NervGen Pharma Corp.
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
May 26, 2026
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
May 22, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
March 13, 2026